ライフサイエンスコーパス: differentiated thyroid cancer

1 s of (123)I and (131)I whole-body imaging in differentiated thyroid cancer.

2 dine for treatment of patients with low-risk differentiated thyroid cancer.

3 uce recurrences and improve survival in well-differentiated thyroid cancer.

4 d remnant or residual tumor in patients with differentiated thyroid cancer.

5 data were reviewed in 347 patients with well-differentiated thyroid cancer.

6 ter partial thyroidectomy for localized well-differentiated thyroid cancer.

7 r and metabolism involved in tumor growth in differentiated thyroid cancer.

8 thyroid follicular cells and are termed well-differentiated thyroid cancer.

9 SDHD in autophagy-associated pathogenesis of differentiated thyroid cancer.

10 Surgery is curative in most cases of well-differentiated thyroid cancer.

11 ared with ablation in patients with low-risk differentiated thyroid cancer.

12 c approach for patient-specific treatment of differentiated thyroid cancer.

13 to the much less aggressive and more common differentiated thyroid cancer.

14 s been largely extrapolated from staging for differentiated thyroid cancer.

15 uman Thyroglobulin (TG), a protein marker of differentiated thyroid cancer.

16 or metastatic, radioactive iodine-refractory differentiated thyroid cancer.

17 erminate nodules that may be associated with differentiated thyroid cancer.

18 TT or lobectomy is often needed to diagnose differentiated thyroid cancer.

19 th progressive radioactive iodine-refractory differentiated thyroid cancer.

20 th progressive radioactive iodine-refractory differentiated thyroid cancer.

21 nizations for the treatment of patients with differentiated thyroid cancer.

22 vels to predict future risk of recurrence of differentiated thyroid cancer.

23 is also a marker of the extent of disease in differentiated thyroid cancers.

24 logical features of human RAS-driven, poorly differentiated thyroid cancers.

25 ly promoted more limited treatments for well-differentiated thyroid cancers.

26 ancers had significantly more CSCs than well-differentiated thyroid cancers.

27 ons in the matched normal tissues or in well-differentiated thyroid cancers.

28 rapidly progressive, radioiodine-refractory differentiated thyroid cancers.

29 herapeutic option for patients with advanced differentiated thyroid cancers.

30 cular cell-derived thyroid cancer are poorly differentiated thyroid cancer (~5%) and anaplastic thyro

31 hyroid autoimmunity has been associated with differentiated thyroid cancer although multiple potentia

32 ge of the molecular pathogenesis of advanced differentiated thyroid cancer and discuss findings from

33 stration-approved for radioiodine-refractory differentiated thyroid cancer and has previously demonst

34 xpressed in ATC and associated with advanced differentiated thyroid cancer and higher mortality rate.

35 downregulation was associated with advanced differentiated thyroid cancer and higher mortality.

36 al growth factor (VEGF) is characteristic of differentiated thyroid cancer and is associated with agg

37 which is downregulated in ATC compared with differentiated thyroid cancer and normal tissue.

38 h a special focus on radioiodine therapy for differentiated thyroid cancer and peptide receptor radio

39 included cohorts of persons treated for well-differentiated thyroid cancer and persons with no surger

40 hyroid or recurrent disease in patients with differentiated thyroid cancer and to evaluate which of t

41 ovides the basis for radioiodine ablation of differentiated thyroid cancers and their metastases.

42 ration, better treatment algorithms for well differentiated thyroid cancer, and more effective treatm

43 nclusion, LOH at 7q31 is a frequent event in differentiated thyroid cancer, and we have defined a 2 c

44 had received at least 1 (131)I treatment for differentiated thyroid cancer, and were responding regar

45 0.99) and decreased odds among patients with differentiated thyroid cancer (AOR, 0.96; 95% CI, 0.94-0

46 Most cases of well-differentiated thyroid cancer are asymptomatic and detec

47 Differentiated thyroid cancers are typically iodine-avid

48 lifetime cancer risks for patients with well differentiated thyroid cancers as part of families with

49 panib in an expanded cohort of patients with differentiated thyroid cancer, as well as in cohorts of

50 a is an uncommon and occasionally aggressive differentiated thyroid cancer associated with increased

51 Among patients treated for well-differentiated thyroid cancer at hospitals in the Nation

52 the role of anthropometric risk factors for differentiated thyroid cancer at the time of diagnosis a

53 The study included 761 adults diagnosed with differentiated thyroid cancer before 35 years of age bet

54 uded 633 young women who were diagnosed with differentiated thyroid cancer before 35 years of age bet

55 derwent surgery, with histopathology showing differentiated thyroid cancer, between May 1, 2016, and

56 In high-activity radioiodine therapies for differentiated thyroid cancer, blood dosimetry has been

57 f circadian clock genes are abnormal in well-differentiated thyroid cancer but not in the benign nodu

58 historically proven ineffective in advanced differentiated thyroid cancers, but the realisation that

59 Patients with differentiated thyroid cancer can often be treated with

60 Hurthle cell carcinoma is an uncommon differentiated thyroid cancer characterized by an aggres

61 of adverse effects of sorafenib when used in differentiated thyroid cancer compared with renal and he

62 tal thyroidectomy in high-risk patients with differentiated thyroid cancer (containing follicular his

63 DECISION trial of sorafenib in patients with differentiated thyroid cancer demonstrated significantly

64 demonstrated the importance of aneuploidy in differentiated thyroid cancer development.

65 e the common oncogenic variants in pediatric differentiated thyroid cancer (DTC) and investigate whet

66 n clinical trials for radioiodine-refractory differentiated thyroid cancer (DTC) and medullary thyroi

67 d-type (BRAF-WT) in patients with metastatic differentiated thyroid cancer (DTC) and poorly different

68 Since the 1980s, both the incidence of differentiated thyroid cancer (DTC) and use of radioacti

69 mplete remission (CR) rates in patients with differentiated thyroid cancer (DTC) at high risk of prim

70 adioactive iodine (RAI) remnant ablation for differentiated thyroid cancer (DTC) facilitates the earl

71 Since thyroglobulin, no new blood tests for differentiated thyroid cancer (DTC) have been introduced

72 Differentiated thyroid cancer (DTC) incidence has been r

73 The incidence of differentiated thyroid cancer (DTC) is increasing.

74 Although differentiated thyroid cancer (DTC) is typically an indo

75 Patients with metastatic differentiated thyroid cancer (DTC) may be prepared usin

76 ce of radioactive iodine ((131)I) therapy in differentiated thyroid cancer (DTC) patients requiring a

77 ent side effects of radioiodine treatment in differentiated thyroid cancer (DTC) patients.

78 Patients with radioiodine-refractory differentiated thyroid cancer (DTC) previously treated w

79 In the past decade, the management of differentiated thyroid cancer (DTC) underwent a paradigm

80 aration for the detection of metastases from differentiated thyroid cancer (DTC) using (131)I WB imag

81 Several susceptibility loci of differentiated thyroid cancer (DTC) were identified by p

82 ge, single-center cohort of patients who had differentiated thyroid cancer (DTC) with that of a match

83 ll established as a successful treatment for differentiated thyroid cancer (DTC), although around 15%

84 merous staging and scoring systems exist for differentiated thyroid cancer (DTC), but all harbor limi

85 ody (TgAb) measurements in the management of differentiated thyroid cancer (DTC), taking into conside

86 For patients with differentiated thyroid cancer (DTC), that is, papillary

87 Differentiated thyroid cancer (DTC), with a rapidly incr

88 tatus and disease-specific survival (DSS) in differentiated thyroid cancer (DTC), with particular att

89 or receptor (VEGFR) pathway have activity in differentiated thyroid cancer (DTC).

90 for radioiodine (RAI) imaging and therapy of differentiated thyroid cancer (DTC).

91 mporter (NIS)-based imaging in patients with differentiated thyroid cancer (DTC).

92 nd approved for radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

93 cancer (ATC) often transforms from indolent differentiated thyroid cancer (DTC); however, the comple

94 prognosis of patients harboring metastasized differentiated thyroid cancer (DTC); identify suitable t

95 ET-PTC expedites optimal initial surgery for differentiated thyroid cancer, facilitating succinct def

96 Several poorly differentiated thyroid cancers harbored DICER1 variants.

97 Radioactive iodine treatment for differentiated thyroid cancer has been associated with s

98 Treatment of differentiated thyroid cancer has been studied for many

99 e reported overexpression of PTTG and PBF in differentiated thyroid cancer has profound implications

100 I)-refractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis beca

101 ly 30% of patients with advanced, metastatic differentiated thyroid cancer have radioiodine-refractor

102 C), and radioactive iodine-refractory (RAIR) differentiated thyroid cancers have a high mortality, pa

103 lar thyroid cancer is the second most common differentiated thyroid cancer histological type and has

104 lasm." Permanent histology demonstrated well-differentiated thyroid cancer in 6 of these 28 patients

105 The optimal treatment of differentiated thyroid cancer in pediatric patients cont

106 Since the pioneering use of (131)I in differentiated thyroid cancer in the 1940s, remarkable a

107 Differentiated thyroid cancer in young patients is assoc

108 T) imaging in the follow-up of patients with differentiated thyroid cancer is an important developmen

109 The extent of primary thyroidectomy for differentiated thyroid cancer is controversial.

110 The incidence of differentiated thyroid cancer is increasing greatly in h

111 Differentiated thyroid cancer is the most common endocri

112 Differentiated thyroid cancer is the most frequent subty

113 rsed more conservative treatment of low-risk differentiated thyroid cancer (LRDTC), yet patients are

114 optimal treatment for younger patients with differentiated thyroid cancer may differ from that for a

115 Unlike differentiated thyroid cancer, nodal metastases predict

116 sTC was defined by histological differentiated thyroid cancer of 1 cm or more and/or lym

117 .7 GBq [100 mCi]) for treating patients with differentiated thyroid cancer or whether the effects of

118 n the practice regarding hospital release of differentiated thyroid cancer patients treated with (131

119 rican Joint Committee on Cancer stage I well-differentiated thyroid cancer patients treated with radi

120 and follow-up (124)I PET/CT data on BMs from differentiated thyroid cancer patients were retrospectiv

121 (124)I PET/CT images from differentiated thyroid cancer patients were retrospectiv

122 ve developed for the long-term monitoring of differentiated thyroid cancer patients.

123 Poorly differentiated thyroid cancer (PDTC) and anaplastic thyr

124 ancers (PTC) that rapidly progress to poorly differentiated thyroid cancer (PDTC).

125 fferentiated thyroid cancer (DTC) and poorly differentiated thyroid cancer (PDTC).

126 Patients with poorly differentiated thyroid cancers (PDTC), anaplastic thyroi

127 t recurrent disease in patients who have had differentiated thyroid cancer, periodic withdrawal of th

128 Children with differentiated thyroid cancer present with more advanced

129 dioiodine in the evaluation of patients with differentiated thyroid cancer, radiolabeled anti-CEA MAb

130 ease in the proportion of patients with well-differentiated thyroid cancer receiving radioactive iodi

131 RAI treatment of differentiated thyroid cancer remains a first-line treat

132 arge randomised trials of patients with well-differentiated thyroid cancer reported in 2012 (HiLo and

133 6-80 years with histological confirmation of differentiated thyroid cancer requiring radioactive iodi

134 mmation, we examined the association between differentiated thyroid cancer risk and the energy-adjust

135 cebo in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).

136 Guidelines for the management of differentiated thyroid cancer should continue to reflect

137 M1 mRNA expression was higher in TNM stage I differentiated thyroid cancers than in stage II and III

138 ne-refractory locally advanced or metastatic differentiated thyroid cancer that had progressed within

139 nses in patients with advanced or metastatic differentiated thyroid cancer that is progressive.

140 y in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to rad

141 that progresses from the highly curable well-differentiated thyroid cancers to the universally fatal

142 se in a cohort of 189,219 patients with well-differentiated thyroid cancer treated at 981 hospitals a

143 All available data regarding differentiated thyroid cancer treatment in children are

144 he blood in patients with surgically treated differentiated thyroid cancer undergoing their first rad

145 In patients with low-risk differentiated thyroid cancer undergoing thyroidectomy,

146 For many patients with differentiated thyroid cancer, use of radioactive iodine

147 proach generally applied in the treatment of differentiated thyroid cancer was assessed using (124)I

148 The incidence of well differentiated thyroid cancer (WDTC) is increasing in th

149 opulation-based cohort of patients with well-differentiated thyroid cancer (WDTC) treated or not with

150 e clinical records of 284 patients with well-differentiated thyroid cancer were reviewed.

151 ased detailed management recommendations for differentiated thyroid cancer, which primarily addressed

152 In patients with newly diagnosed differentiated thyroid cancer who had undergone thyroide

153 ample included adult patients without poorly differentiated thyroid cancer who underwent thyroidectom

154 3 trial, we assigned patients with low-risk differentiated thyroid cancer who were undergoing thyroi

155 o I-131 treatment for patients with advanced differentiated thyroid cancer will provide critical info

156 dvanced or metastatic, radioiodine-resistant differentiated thyroid cancer with 125 mg of motesanib d

157 sed on 16 studies (n = 291796), treatment of differentiated thyroid cancer with radioactive iodine is

158 Many patients with low-risk differentiated thyroid cancer worldwide can safely avoid